Fibrin-targeting peptide CREKA-conjugated multi-walled carbon nanotubes for self-amplified photothermal therapy of tumor

Zhang, Bo; Wang, Huafang; Shen, Shun; She, Xiaojian; Shi, Wei; Chen, Jun; Zhang, Qizhi; Hu, Yu; Pang, Zhiqing; Jiang, Xinguo

doi:10.1016/j.biomaterials.2015.11.061

Cited by 114 publications

(84 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both our and other studies had recently found that CREKA could specifically bind to fibrin in microthrombus and stroma of tumors. [34][35][36][37] It occurred to us that CREKA peptide could mediate nanoparticle (NP) drug delivery system to fibrin in infarcted myocardium, which may increase the retention of Tβ4, improve its efficacy, and reduce its dosing systematically.…”

mentioning

confidence: 99%

“…It was shown to specifically and quantitatively bind to fibrin in the blood vessels and stroma of tumor. 34 In recent years, this peptide has been used in the targeting detection of fibrin in both atherosclerosis 35 and microthrombus. 36 Meanwhile, the surface density of ligands on NPs is an important factor that determines multivalent effects of ligands-modified NPs, which can dramatically enhance targeting specificity and efficiency of drug delivery and has been successfully verified in tumor imaging and therapy.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles

Huang

Song

Pang

et al. 2017

IJN

Self Cite

View full text Add to dashboard Cite

Purpose Thymosin beta 4 (Tβ4) has multiple beneficial facets for myocardial injury, but its efficiency is limited by the low local concentration within the infarct. Here, we established a Tβ4 delivery system for cardiac repair based on the interaction between the abundant fibrin in the infarct zone and the fibrin-targeting moiety clot-binding peptide cysteine–arginine–glutamic acid–lysine–alanine (CREKA). Methods and results CREKA and Tβ4 were conjugated to nanoparticles (CNP–Tβ4). In vitro binding test revealed that CNP–Tβ4 had a significant binding ability to the surface of fibrin clots when compared to the control clots (NP–Tβ4). Based on the validation of fibrin expression in the early stage of ischemia injury, CNP–Tβ4 was intravenously administered to mice with acute myocardial ischemia–reperfusion injury. CNP–Tβ4 revealed a stronger fibrin-targeting ability than the NP–Tβ4 group and accumulated mainly in the infarcted area and colocalized with fibrin. Subsequently, treatment with CNP–Tβ4 resulted in a better therapeutic effect. Conclusion CRKEA modification favored Tβ4 accumulation and retention in the infarcted region, leading to augmented functional benefits. Fibrin-targeting delivery system represents a generalizable platform technology for regenerative medicine.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles

Huang

Song

Pang

et al. 2017

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

“…Blood samples were drawn from tail vein at 0.17, 0.5, 1, 3, 8, and 24 h following administration. The DiR-labelled PGG-PTX nanoconjugates and AS1411-PGG-PTX nanoconjugates in blood samples were quantified by a Tecan Infinite M200 Pro Multiplate Reader (Switzerland) with the excitation wave length of 745 nm and emission wave length of 780 nm [47].…”

Section: Distribution Of As1411-pgg-ptx Nanoconjugates In Glioma Slicesmentioning

confidence: 99%

Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (l-γ-glutamylglutamine)–paclitaxel nanoconjugates

Luo

Yan

Jin

et al. 2017

Journal of Colloid and Interface Science

Self Cite

View full text Add to dashboard Cite

“…Due to their excellent chemical and physical properties, several studies have suggested CNTs as a carrier designed to be a drug delivery system in cancer treatment (20,21). However, there are no studies on CNTs as a drug delivery carrier material with recombinant human (rh)-EGF.…”

Section: Introductionmentioning

confidence: 99%

Preparation and properties of a novel carbon nanotubes/poly(vinyl alcohol)/epidermal growth factor composite biological dressing

Liao

Wang

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Wound dressings with drug delivery system have drawn increasing attention in skin damage recombination. Herein, a novel composite biological dressing was prepared and based on poly(vinyl alcohol) (PVA) combined with carbon nanotubes (CNTs) and epidermal growth factor (EGF) by electrospinning on gauze. The properties of the CNTs/PVA/EGF composite dressing were systemically investigated by general observation, and scanning electron microscopy (SEM). In vitro, the cytotoxicity of this dressing was investigated using a methyl thiazolyl tetrazolium (MTT) assay on L929 fibroblasts. In order to study the sustained release of EGF from this dressing, the concentration of EGF at different times was tested by ELISA. Furthermore, the biological activity of the released EGF was also evaluated using the MTT assay. Moreover, an in vivo experiment was conducted to observe whether this dressing was capable of improving healing in the model of wounded skin on rats. It was revealed that this dressing had a well-distributed microstructure by SEM. Additionally, the grade of cytotoxicity was low, and the EGF had a sustained release rate from this dressing. Furthermore, a maximum accumulative release rate of 12.47% was identified at 12 h, and was retained at 9.4% after 48 h. Simultaneously, the relative growth rate of L929 fibroblasts in the 12 h experimental group and 48 h group was 291.24 and 211.3%, respectively. Next, the efficacy of these products was evaluated in vivo using Sprague-Dawley rats with a skin injury model. The healing of wounded skin of rats was sped up by this dressing based on the gross and histological appearances. From 7 to 10 days, the wounds in the experimental group were almost healed. In conclusion, this CNTs/PVA/EGF dressing had a well-distributed structure and an ability to release EGF at a sustained rate with the activity being favorable. On the basis of those results, a positive influence of designed dressing for accelerated wound healing was confirmed.

show abstract

Fibrin-targeting peptide CREKA-conjugated multi-walled carbon nanotubes for self-amplified photothermal therapy of tumor

Cited by 114 publications

References 51 publications

Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles

Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles

Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (l-γ-glutamylglutamine)–paclitaxel nanoconjugates

Preparation and properties of a novel carbon nanotubes/poly(vinyl alcohol)/epidermal growth factor composite biological dressing

Contact Info

Product

Resources

About